Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations

Keywords

Osimertinib, T790M, Medicine, Adenocarcinoma, Lung cancer

References

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung CancersAntonio Tomás Palacios García — 2013
• EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIsYoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe — 2015
• Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitorsKazuto Furuyama, Taishi Harada, Eiji Iwama — 2013
• Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater — 2015
• Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung CancerJenn‐Yu Wu, Chong‐Jen Yu, Yeun‐Chung Chang — 2011
• Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyYoshihisa Kobayashi, Tetsuya Mitsudomi — 2016
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerTony Mok, Yi‐Long Wu, Myung‐Ju Ahn — 2016
• EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of OsimertinibSuzanne Jenkins, James Chih‐Hsin Yang, Pasi A. Jänne — 2017
• Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.Roberta Minari, Paola Bordi, Marzia Del Re — 2018
• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung CancerJean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste — 2018
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.David Planchard, Sanjay Popat, Keith M. Kerr — 2018

Cited by

• Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768ISeigo Minami, Shouichi Ihara, Tsunehiro Tanaka — 2019
• Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired ResistanceEric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska — 2019
• Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.Shuo Yang, Shiqi Mao, Xuefei Li — 2019
• The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal.Valerio Gristina, Umberto Malapelle, Antonio Galvano — 2020
• Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.Yen‐Ting Lin, Tzu-Hsiu Tsai, Shang‐Gin Wu — 2020
• MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinibAkihiro Nishiyama, Shinji Takeuchi, Yuta Adachi — 2020
• Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor modelHiroshi Ikeuchi, Takeshi Hirose, Masachika Ikegami — 2022
• Afatinib2019
• Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with EGFR G719X/L861Q/S768ILanlan Pang, Jiadi Gan, Jiaming Tan — 2022
• 1 Intrinsic resistance to EGFR-tyrosine kinase 2 inhibitors in EGFR-mutant non-small cell lung 3 cancer : differences and similarities with acquired 4 resistance 5E. Santoni-Rugiu, L. Melchior, E. Urbanska — 2019

Related papers

• Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.Roberta Minari, Paola Bordi, Marzia Del Re — 2018
• Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.Jia-Tao Cheng, Jin‐Ji Yang, Yi‐Long Wu — 2019
• P3.01-037 Understanding Mechanisms of Resistance to Osimertinib by Circulating Tumor DNA Genotyping in Advanced Non-Small-Cell Lung CancerYingying Du, Wanchun Zang, G. Wang — 2017
• P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC: Topic: EGFR BiomarkersAnna Buder, Maximilian J. Hochmair, Sophia Holzer — 2017
• EP12.01-23 Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case ReportKijjakom Thanasombunsukh, B. Chamnongprasatporn, P. Chiravirakul — 2023
• MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC PatientsShun Wang, B. Zhang, Bei Han — 2018
• Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M MutationKana Watanabe, Ryota Saito, Eisaku Miyauchi — 2023
• JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC PatientsShun Wang, B. Zhang, Baohui Han — 2018
• Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialJuliann Chmielecki, Tony Mok, Yi‐Long Wu — 2023
• Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinibOu Yamaguchi, Norimitsu Kasahara, Hiroshi Soda — 2023